Kintsugi Raises $20M for Depression & Anxiety Biomarker Diagnostic

Kintsugi, a startup that aims to identify signs of depression and anxiety using vocal biomarkers, scored $20 million in Series A funding, per Mobi Health News. The latest round comes about six months after the company announced it had raised $8 million in seed funding. 

The Series A was led by Insight Partners, with participation from Acrew Capital, Darling Ventures, Citta Capital, Side Door Ventures, Primetime Partners, IT Farm, AngelList Fund and Alpha Edison. 

Total
0
Shares
Related Posts